151 related articles for article (PubMed ID: 22198210)
1. A review of transcriptome studies combined with data mining reveals novel potential markers of malignant pleural mesothelioma.
Melaiu O; Cristaudo A; Melissari E; Di Russo M; Bonotti A; Bruno R; Foddis R; Gemignani F; Pellegrini S; Landi S
Mutat Res; 2012; 750(2):132-140. PubMed ID: 22198210
[TBL] [Abstract][Full Text] [Related]
2. Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma.
Kopecka J; Salaroglio IC; Righi L; Libener R; Orecchia S; Grosso F; Milosevic V; Ananthanarayanan P; Ricci L; Capelletto E; Pradotto M; Napoli F; Di Maio M; Novello S; Rubinstein M; Scagliotti GV; Riganti C
Lung Cancer; 2018 Jun; 120():34-45. PubMed ID: 29748013
[TBL] [Abstract][Full Text] [Related]
3. Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications.
Suraokar MB; Nunez MI; Diao L; Chow CW; Kim D; Behrens C; Lin H; Lee S; Raso G; Moran C; Rice D; Mehran R; Lee JJ; Pass HI; Wang J; Momin AA; James BP; Corvalan A; Coombes K; Tsao A; Wistuba II
Ann Oncol; 2014 Jun; 25(6):1184-92. PubMed ID: 24669013
[TBL] [Abstract][Full Text] [Related]
4. MicroRNAs dysregulation in human malignant pleural mesothelioma.
Balatti V; Maniero S; Ferracin M; Veronese A; Negrini M; Ferrocci G; Martini F; Tognon MG
J Thorac Oncol; 2011 May; 6(5):844-51. PubMed ID: 21358347
[TBL] [Abstract][Full Text] [Related]
5. Expression status of candidate genes in mesothelioma tissues and cell lines.
Melaiu O; Melissari E; Mutti L; Bracci E; De Santi C; Iofrida C; Di Russo M; Cristaudo A; Bonotti A; Cipollini M; Garritano SI; Foddis R; Lucchi M; Pellegrini S; Gemignani F; Landi S
Mutat Res; 2015 Jan; 771():6-12. PubMed ID: 25771974
[TBL] [Abstract][Full Text] [Related]
6. MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma.
Melaiu O; Stebbing J; Lombardo Y; Bracci E; Uehara N; Bonotti A; Cristaudo A; Foddis R; Mutti L; Barale R; Gemignani F; Giamas G; Landi S
PLoS One; 2014; 9(1):e85935. PubMed ID: 24465798
[TBL] [Abstract][Full Text] [Related]
7. Differentially expressed alternatively spliced genes in malignant pleural mesothelioma identified using massively parallel transcriptome sequencing.
Dong L; Jensen RV; De Rienzo A; Gordon GJ; Xu Y; Sugarbaker DJ; Bueno R
BMC Med Genet; 2009 Dec; 10():149. PubMed ID: 20043850
[TBL] [Abstract][Full Text] [Related]
8. Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed.
Cortes-Dericks L; Carboni GL; Schmid RA; Karoubi G
Int J Oncol; 2010 Aug; 37(2):437-44. PubMed ID: 20596671
[TBL] [Abstract][Full Text] [Related]
9. p53 modeling as a route to mesothelioma patients stratification and novel therapeutic identification.
Tian K; Bakker E; Hussain M; Guazzelli A; Alhebshi H; Meysami P; Demonacos C; Schwartz JM; Mutti L; Krstic-Demonacos M
J Transl Med; 2018 Oct; 16(1):282. PubMed ID: 30316293
[TBL] [Abstract][Full Text] [Related]
10. Sequential binary gene ratio tests define a novel molecular diagnostic strategy for malignant pleural mesothelioma.
De Rienzo A; Richards WG; Yeap BY; Coleman MH; Sugarbaker PE; Chirieac LR; Wang YE; Quackenbush J; Jensen RV; Bueno R
Clin Cancer Res; 2013 May; 19(9):2493-502. PubMed ID: 23493352
[TBL] [Abstract][Full Text] [Related]
11. The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma.
Pignochino Y; Dell'Aglio C; Inghilleri S; Zorzetto M; Basiricò M; Capozzi F; Canta M; Piloni D; Cemmi F; Sangiolo D; Gammaitoni L; Soster M; Marchiò S; Pozzi E; Morbini P; Luisetti M; Aglietta M; Grignani G; Stella GM
BMC Cancer; 2015 May; 15():374. PubMed ID: 25952930
[TBL] [Abstract][Full Text] [Related]
12. Analysis of microRNA expression signatures in malignant pleural mesothelioma, pleural inflammation, and atypical mesothelial hyperplasia reveals common predictive tumorigenesis-related targets.
Ramírez-Salazar EG; Salinas-Silva LC; Vázquez-Manríquez ME; Gayosso-Gómez LV; Negrete-Garcia MC; Ramírez-Rodriguez SL; Chávez R; Zenteno E; Santillán P; Kelly-García J; Ortiz-Quintero B
Exp Mol Pathol; 2014 Dec; 97(3):375-85. PubMed ID: 25236577
[TBL] [Abstract][Full Text] [Related]
13. The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?
Bronte G; Incorvaia L; Rizzo S; Passiglia F; Galvano A; Rizzo F; Rolfo C; Fanale D; Listì A; Natoli C; Bazan V; Russo A
Crit Rev Oncol Hematol; 2016 Nov; 107():20-32. PubMed ID: 27823648
[TBL] [Abstract][Full Text] [Related]
14. Inhibitor of apoptosis proteins are regulated by tumour necrosis factor-alpha in malignant pleural mesothelioma.
Gordon GJ; Mani M; Mukhopadhyay L; Dong L; Yeap BY; Sugarbaker DJ; Bueno R
J Pathol; 2007 Mar; 211(4):439-46. PubMed ID: 17253597
[TBL] [Abstract][Full Text] [Related]
15. Wnt/IL-1β/IL-8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5.
Milosevic V; Kopecka J; Salaroglio IC; Libener R; Napoli F; Izzo S; Orecchia S; Ananthanarayanan P; Bironzo P; Grosso F; Tabbò F; Comunanza V; Alexa-Stratulat T; Bussolino F; Righi L; Novello S; Scagliotti GV; Riganti C
Int J Cancer; 2020 Jan; 146(1):192-207. PubMed ID: 31107974
[TBL] [Abstract][Full Text] [Related]
16. Malignant pleural mesothelioma: genome-wide expression patterns reflecting general resistance mechanisms and a proposal of novel targets.
Røe OD; Anderssen E; Sandeck H; Christensen T; Larsson E; Lundgren S
Lung Cancer; 2010 Jan; 67(1):57-68. PubMed ID: 19380173
[TBL] [Abstract][Full Text] [Related]
17. Impact of metallothionein-knockdown on cisplatin resistance in malignant pleural mesothelioma.
Borchert S; Suckrau PM; Walter RFH; Wessolly M; Mairinger E; Steinborn J; Hegedus B; Hager T; Herold T; Eberhardt WEE; Wohlschlaeger J; Aigner C; Bankfalvi A; Schmid KW; Mairinger FD
Sci Rep; 2020 Oct; 10(1):18677. PubMed ID: 33122816
[TBL] [Abstract][Full Text] [Related]
18. A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma.
Phillips MM; Pavlyk I; Allen M; Ghazaly E; Cutts R; Carpentier J; Berry JS; Nattress C; Feng S; Hallden G; Chelala C; Bomalaski J; Steele J; Sheaff M; Balkwill F; Szlosarek PW
Pharmacol Rep; 2023 Jun; 75(3):570-584. PubMed ID: 37010783
[TBL] [Abstract][Full Text] [Related]
19. Prognostic and Therapeutic Implications of MicroRNA in Malignant Pleural Mesothelioma.
Truini A; Coco S; Genova C; Mora M; Dal Bello MG; Vanni I; Alama A; Rijavec E; Barletta G; Biello F; Maggioni C; Grossi F
Microrna; 2016; 5(1):12-18. PubMed ID: 26817512
[TBL] [Abstract][Full Text] [Related]
20. Cell protection, resistance and invasiveness of two malignant mesotheliomas as assessed by 10K-microarray.
Mohr S; Keith G; Galateau-Salle F; Icard P; Rihn BH
Biochim Biophys Acta; 2004 Jan; 1688(1):43-60. PubMed ID: 14732480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
